NorthWest Biotherapeutics Inc (NWBO)

[reachjo]

Additional point. INmune’s quarterly financial report is due on August 11. Meaning INmune can be best valued at that point in terms of worth. I fully expect a merger or aquisition between the two companies this year.

Why?

1. Faster gateway to NASDAQ
2. Complimentary product lines that can be manufactured in existing infrastructure. INmune has only 7 employees and zero capability of production at this point.
3. INmune is the perfect size to acquire or merge with.
4. Full product portfolio focusing on dendritic cells and NK cells. Many disease states would be covered.

With all that the company would become a full portfolio biotech company with a high valuation.
In my opinion, news will come on or after Aug 12.